$3.26
+0.01
(+0.31%)▲
Live
3.75%
Downside
Day's Volatility :8.94%
Upside
5.4%
15.95%
Downside
52 Weeks Volatility :97.79%
Upside
97.37%
Period | Sintx Technologies Inc | Index (Russel 2000) |
---|---|---|
3 Months | -34.74% | 0.0% |
6 Months | -57.24% | 0.0% |
1 Year | -96.95% | 0.0% |
3 Years | -99.99% | -23.0% |
Market Capitalization | 2.2M |
Book Value | $11.82 |
Earnings Per Share (EPS) | -2903.36 |
Wall Street Target Price | 70.0 |
Profit Margin | -275.14% |
Operating Margin TTM | -275.9% |
Return On Assets TTM | -40.13% |
Return On Equity TTM | -75.92% |
Revenue TTM | 3.1M |
Revenue Per Share TTM | 16.44 |
Quarterly Revenue Growth YOY | 69.1% |
Gross Profit TTM | 1.3M |
EBITDA | -10.0M |
Diluted Eps TTM | -2903.36 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -19.12 |
EPS Estimate Next Year | -11.73 |
EPS Estimate Current Quarter | -996.2 |
EPS Estimate Next Quarter | -425.3 |
What analysts predicted
Upside of 2047.24%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 95.0K | ↓ 99.38% |
Net Income | -8.7M | ↓ 47.87% |
Net Profit Margin | -9.1K% | ↓ 8998.36% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 689.0K | ↑ 625.26% |
Net Income | -4.8M | ↓ 43.96% |
Net Profit Margin | -703.77% | ↑ 8403.6% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 594.0K | ↓ 13.79% |
Net Income | -7.3M | ↑ 50.81% |
Net Profit Margin | -1.2K% | ↓ 527.37% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 606.0K | ↑ 2.02% |
Net Income | -9.8M | ↑ 34.32% |
Net Profit Margin | -1.6K% | ↓ 389.82% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 601.0K | ↓ 0.83% |
Net Income | -16.5M | ↑ 67.86% |
Net Profit Margin | -2.7K% | ↓ 1122.63% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 2.6M | ↑ 337.1% |
Net Income | -8.3M | ↓ 49.91% |
Net Profit Margin | -314.39% | ↑ 2429.2% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 240.0K | ↓ 2.83% |
Net Income | 3.0M | ↓ 135.31% |
Net Profit Margin | 1.2K% | ↑ 4641.13% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 235.0K | ↓ 2.08% |
Net Income | -2.5M | ↓ 182.69% |
Net Profit Margin | -1.0K% | ↓ 2281.76% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 678.0K | ↑ 188.51% |
Net Income | -3.2M | ↑ 29.94% |
Net Profit Margin | -470.5% | ↑ 574.18% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 902.0K | ↑ 33.04% |
Net Income | -2.3M | ↓ 27.24% |
Net Profit Margin | -257.32% | ↑ 213.18% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 687.0K | ↓ 23.84% |
Net Income | -886.0K | ↓ 61.83% |
Net Profit Margin | -128.97% | ↑ 128.35% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 859.0K | ↑ 25.04% |
Net Income | -2.2M | ↑ 148.76% |
Net Profit Margin | -256.58% | ↓ 127.61% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 11.5M | ↓ 56.15% |
Total Liabilities | 3.1M | ↓ 73.79% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 9.1M | ↓ 20.56% |
Total Liabilities | 3.9M | ↑ 26.6% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 30.4M | ↑ 232.86% |
Total Liabilities | 4.6M | ↑ 17.69% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 21.8M | ↓ 28.27% |
Total Liabilities | 4.1M | ↓ 11.44% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 15.8M | ↓ 27.78% |
Total Liabilities | 10.1M | ↑ 144.87% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 15.4M | ↓ 2.59% |
Total Liabilities | 6.6M | ↓ 34.52% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 22.7M | ↑ 43.61% |
Total Liabilities | 6.7M | ↓ 33.4% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 19.1M | ↓ 15.69% |
Total Liabilities | 5.3M | ↓ 21.18% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 15.5M | ↓ 18.78% |
Total Liabilities | 4.8M | ↓ 8.76% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 15.4M | ↓ 0.95% |
Total Liabilities | 6.6M | ↑ 36.7% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 17.6M | ↑ 14.29% |
Total Liabilities | 7.6M | ↑ 15.8% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 15.3M | ↓ 12.9% |
Total Liabilities | 6.5M | ↓ 15.52% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -9.3M | ↑ 30.38% |
Investing Cash Flow | -145.0K | ↓ 87.25% |
Financing Cash Flow | 14.4M | ↑ 347.65% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -6.4M | ↓ 31.16% |
Investing Cash Flow | 1.4M | ↓ 1052.41% |
Financing Cash Flow | 1.4M | ↓ 90.32% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -9.1M | ↑ 41.6% |
Investing Cash Flow | 1.8M | ↑ 26.79% |
Financing Cash Flow | 30.9M | ↑ 2118.44% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -10.1M | ↑ 11.19% |
Investing Cash Flow | -1.7M | ↓ 194.29% |
Financing Cash Flow | 705.0K | ↓ 97.72% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -10.3M | ↑ 1.29% |
Investing Cash Flow | -1.1M | ↓ 33.31% |
Financing Cash Flow | 3.3M | ↑ 373.19% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -4.9M | ↑ 133.85% |
Investing Cash Flow | -236.0K | ↓ 20.27% |
Financing Cash Flow | 11.5M | ↑ 198.78% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -3.2M | ↓ 34.31% |
Investing Cash Flow | -98.0K | ↓ 58.47% |
Financing Cash Flow | -88.0K | ↓ 100.77% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -2.9M | ↓ 8.87% |
Investing Cash Flow | -105.0K | ↑ 7.14% |
Financing Cash Flow | -88.0K | ↑ 0.0% |
Sell
Neutral
Buy
Sintx Technologies Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Sintx Technologies Inc | -8.71% | -57.24% | -96.95% | -99.99% | -99.99% |
Stryker Corporation | 0.83% | 12.78% | 40.21% | 33.69% | 71.83% |
Boston Scientific Corp. | 4.85% | 29.48% | 75.68% | 96.28% | 127.87% |
Edwards Lifesciences Corp. | 4.32% | -19.19% | 1.77% | -39.29% | -7.22% |
Abbott Laboratories | 3.99% | 11.51% | 24.65% | -4.53% | 46.22% |
Medtronic Plc | 2.65% | 14.48% | 27.42% | -24.18% | -13.49% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Sintx Technologies Inc | NA | NA | NA | -19.12 | -0.76 | -0.4 | NA | 11.82 |
Stryker Corporation | 40.15 | 40.15 | 2.64 | 12.01 | 0.19 | 0.07 | 0.01 | 51.86 |
Boston Scientific Corp. | 70.26 | 70.26 | 2.14 | 2.41 | 0.09 | 0.05 | NA | 13.85 |
Edwards Lifesciences Corp. | 27.67 | 27.67 | 3.65 | 2.6 | 0.22 | 0.12 | NA | 12.35 |
Abbott Laboratories | 35.83 | 35.83 | 4.31 | 4.67 | 0.14 | 0.06 | 0.02 | 22.26 |
Medtronic Plc | 30.23 | 30.23 | 1.67 | 5.2 | 0.08 | 0.04 | 0.03 | 37.39 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Sintx Technologies Inc | Buy | $2.2M | -99.99% | NA | -275.14% |
Stryker Corporation | Buy | $137.1B | 71.83% | 40.15 | 16.12% |
Boston Scientific Corp. | Buy | $127.3B | 127.87% | 70.26 | 12.0% |
Edwards Lifesciences Corp. | Buy | $42.3B | -7.22% | 27.67 | 23.74% |
Abbott Laboratories | Buy | $205.1B | 46.22% | 35.83 | 13.65% |
Medtronic Plc | Buy | $115.2B | -13.49% | 30.23 | 12.06% |
Insights on Sintx Technologies Inc
Revenue is up for the last 2 quarters, 687.0K → 859.0K (in $), with an average increase of 20.0% per quarter
Netprofit is down for the last 2 quarters, -886.0K → -2.20M (in $), with an average decrease of 148.8% per quarter
In the last 1 year, Boston Scientific Corp. has given 76.0% return, outperforming this stock by 173.2%
In the last 3 years, Boston Scientific Corp. has given 96.3% return, outperforming this stock by 196.3%
UBS Group AG
Tower Research Capital LLC
SignatureFD, LLC
Citigroup Inc
Headlands Technologies LLC
HRT FINANCIAL LLC
amedica is the only manufacturer of medical grade silicon nitride, an innovative biomaterial technology ideal for use in spinal fusion and across a variety of medical applications. our silicon nitride features a unique nanosurface texture that promotes bone growth and addresses clinical needs by providing excellent imaging capabilities and demonstrating antibacterial characteristics. our interbody fusion devices and pedicle screw systems are designed to benefit both the patient and the surgeon. with the only fda registered and iso 1345 certified silicon nitride medical device manufacturing facility in the world and a strong sales and distribution organization, we are committed to providing innovative healthcare solutions that improve patient quality of life.
Organization | Sintx Technologies Inc |
Employees | 43 |
CEO | Mr. Eric K. Olson |
Industry | Health Technology |
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$3.26
+0.31%
Invesco Bulletshares 2025 Hi
$3.26
+0.31%
Schwab International Dividend Equity Etf
$3.26
+0.31%
Blockchain Coinvestors Acquisition Corp.
$3.26
+0.31%
Allgiant Travel Company
$3.26
+0.31%
Rogers Corp
$3.26
+0.31%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$3.26
+0.31%
Iheartmedia
$3.26
+0.31%
Lightpath Technologies Inc
$3.26
+0.31%